COMP and non-small cell lung carcinoma: Our findings suggest that elevated levels of COMP expression may be used as a biomarker for patients with radiation resistant NSCLC, and downstream signaling intermediates of COMP could be targeted to reverse the radiation resistance conferred by COMP.